Project Grant K01CA312882
Award Date 8/18/26
Completion Date 7/31/31
Dollars Obligated $200K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $756,755 on August 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a structured peer support intervention for patients undergoing hematopoietic stem cell transplantation. The award is classified as a Project Grant with a period of performance through July 31, 2031, and place of performance in Boston, Massachusetts. The intervention, called STEPP (Structured Peer Support Intervention),...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $155,605 on September 12, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research identifying metabolomic profiles associated with oral contraception use and their relationship to ovarian and breast cancer risk. The project, led by Dr. Mongiovi, will comprehensively quantify changes in circulating metabolites and metabolic pathways linked to oral contraceptive use using machine learning and...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $645,233 on August 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate hormone regulation of fallopian tube inflammation and cancer initiation via a stromal niche. The project examines how estrogen signaling in fallopian tube stromal cells drives chronic inflammation and promotes ovarian cancer initiation. The research builds on preliminary findings identifying estrogen receptor-positive...
- This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
- The National Cancer Institute awarded The MGH Institute of Health Professions, Inc. $696,498 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and optimize a multicomponent intervention for improving functional recovery and participation in life roles among breast cancer survivors. The research uses the Multiphase Optimization Strategy (MOST) framework to systematically test three remotely delivered intervention components: priority elicitation to...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $529,801 on July 9, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mechanisms by which opioid hormone signaling suppresses CD8+ tumor-infiltrating lymphocyte function and impairs immune checkpoint blockade efficacy in cancer. The research uses single-cell RNA sequencing and functional studies to characterize how tumor-derived opioids—specifically proenkephalin-derived peptides acting through...
- Brigham & Women's Hospital Inc. was awarded a $1,523,784 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program to investigate cytoplasmic DNA-sensing pathways in BRCA1-deficient breast cancer development. The three-year award beginning July 1, 2022 will support research into medical solutions for breast cancer at the cellular level through studying the role of cytoplasmic DNA sensors in breast cancer tumor growth associated with...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $340,737 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize and pilot test Healing Gardens, a serious game delivering cognitive behavioral therapy for pain tailored to advanced cancer patients managing chronic pain with opioids. Healing Gardens integrates multimedia cancer pain education with mini-games and gamified elements—including 2D animations, interactive feedback, and visual...
- The National Institute of Biomedical Imaging and Bioengineering awarded Brigham & Women's Hospital Inc. $1,583,125 on May 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a multifunctional interventional device for biopsy and optical imaging-based phase-0 drug response measurements. The recipient will develop an interventional drug response assay (IDRA) device to enable biopsy-based phase-0 measurements...
- The National Institutes of Health's National Cancer Institute awarded $331,085.91 under the Cancer Research Manpower federal grant program (CFDA 93.398) to Brigham & Women's Hospital Inc. on February 1, 2021 for completion by September 30, 2022. The project grant funding will support research investigating the role of cellular senescence in chemotherapy-related cognitive impairment and the contribution of microglia to chemotherapy-induced senescence in the brain. Specifically, the grantee...